XOR Levels in OSA Patients (XOR-OSA)

Recruiting now · Not applicable

Conditions studied: Obstructive Sleep Apnea

In brief

The level of xanthine oxidoreductase (XOR) in plasma is associated with oxidative stress and inflammation. Obstructive Sleep Apnea (OSA) is characterized by repeated upper airway obstruction and apneas during sleep, leading to chronic intermittent hypoxemia. The specific role of XOR in OSA, its relationship with the severity of OSA, and the changes in XOR levels before and after CPAP treatment remain unclear. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University, categorized by their Apnea-Hypopnea Index (AHI) into mild, moderate, and severe OSA groups. Participants will undergo baseline assessments including polysomnography (PSG) and measurements of XOR activity and biomarkers such as uric acid, endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), and inflammatory markers. Eligible patients will receive CPAP treatment for 3 months, after which their XOR activity and biomarker levels will be re-evaluated to assess treatment efficacy.

Key facts

Study ID

NCT06554496

Run by

Nanjing Medical University

People needed

80

Starts

2024-07-01

Expected to finish

2025-12-31

Last updated by the study team

2024-08-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged between 18 and 80 years.
• Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)(apnea-hypopnea index≥5/h).
• First-time diagnosis, with no previous surgical interventions or CPAP treatment for OSA.
• Ability and willingness to provide informed consent for participation in the study.

You may not qualify if…

• History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results.
• Presence of active malignancies or other severe underlying diseases, such as severe liver or kidney dysfunction. Diagnosed with diabetes or other significant vascular diseases.
• Presence of severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure caused by any condition.
• Pregnancy or having other conditions that make participation in this study unsuitable.
• Extremely debilitated patients or those with severe underlying conditions.

Where it is running

• The First Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.